Carnelian Invests ₹100 Crore in Park Medi World Ahead of ₹1,260 Crore IPO

In a major pre-IPO development, Carnelian Asset Management has invested ₹100 crore in Park Medi World, the operator of the Park Hospitals network. The investment, executed through a secondary share purchase, signals growing institutional interest in India’s healthcare sector ahead of the company’s public listing.

Park Medi World’s Healthcare Network

Park Medi World Ltd., headquartered in Gurugram, Haryana, operates one of North India’s fastest-growing private hospital networks under the Park Hospitals brand. The company specialises in multi-super-speciality healthcare, offering advanced services in oncology, cardiology, orthopaedics, and critical care.

Carnelian’s ₹100 Crore Investment

According to regulatory disclosures, Ajit Gupta, one of the promoters of Park Medi World, sold 61,72,840 equity shares representing about 1.6% of the company’s total stake on 18 October 2025 at ₹162 per share, totalling approximately ₹100 crore.

The transaction was executed by Carnelian Bharat Amritkaal Fund, Carnelian Bharat Amritkaal Fund–2, and Carnelian Asset Management & Advisors Pvt Ltd through a secondary share transfer. This marks a strategic pre-IPO positioning by Carnelian ahead of Park Medi World’s public debut.

Regulatory Approval for ₹1,260 Crore IPO

Earlier in March 2025, Park Medi World filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for a proposed ₹1,260 crore Initial Public Offering (IPO). The issue includes a fresh issue of shares and an offer-for-sale (OFS) component.

In August 2025, SEBI granted regulatory approval for the IPO, clearing the path for Park Medi World to tap the primary market. The fresh issue proceeds are planned for debt repayment, capital expenditure, and expansion of medical infrastructure.

Growth Plans and Utilisation of Funds

The funds will also help in developing a new hospital and expanding an existing facility through subsidiaries Park Medicity (NCR) and Blue Heavens. These initiatives aim to strengthen the company’s footprint in North India’s healthcare market.

Read More: India's Pharma Exports to Cross $30 Billion.

Conclusion

Carnelian’s ₹100 crore investment in Park Medi World underscores strong institutional interest ahead of the company’s ₹1,260 crore IPO. With regulatory approval secured and expansion plans in place, Park Medi World is positioned to scale its healthcare network and enhance medical infrastructure.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.